Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 261Neoplasms 143Breast Neoplasms 140Colorectal Neoplasms 124Prostatic Neoplasms 94Neoplasm Metastasis 93Multiple Myeloma 92Ovarian Neoplasms 91Lung Neoplasms 86Squamous Cell Carcinoma of Head and Neck 62Pancreatic Neoplasms 62Recurrence 59Endometrial Neoplasms 55Melanoma 52Small Cell Lung Carcinoma 51Leukemia, Lymphocytic, Chronic, B-Cell 48Stomach Neoplasms 47Carcinoma, Renal Cell 46Leukemia, Myeloid, Acute 44Lymphoma, Non-Hodgkin 40Advanced Solid Tumors 39Urinary Bladder Neoplasms 37Triple Negative Breast Neoplasms 36Parkinson Disease 4, Autosomal Dominant Lewy Body 36Lymphoma, Large B-Cell, Diffuse 36Head and Neck Neoplasms 36Carcinoma, Hepatocellular 35Lymphoma, Follicular 30Esophageal Neoplasms 30Myasthenia Gravis 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Gastro-enteropancreatic neuroendocrine tumor × 30 days × Clear all
NCT05636618 2026-05-14

Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors

Perspective Therapeutics

Phase 1/2 Recruiting
300 enrolled
CNSEndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Meningioma, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡